Renalytix plc
Renalytix plc
No insider data available
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||
Assets Current | |||||||||||
Cash And Cash Equivalents At Carrying Value | 1 | 5 | 5 | 6 | 14 | 25 | |||||
Accounts Receivable Net Current | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 2 | 1 | |||||
Assets Current | 3 | 6 | 6 | 8 | 16 | 27 | |||||
Notes And Loans Receivable Net Current | - | - | - | - | - | 0 | |||||
Property Plant And Equipment Net | 0 | 0 | 0 | 1 | 1 | 1 | |||||
Operating Lease Right Of Use Asset | - | 0 | 0 | 0 | 0 | 0 | |||||
Investment Owned At Fair Value | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Other Assets | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Assets | 5 | 8 | 9 | 11 | 20 | 31 | |||||
Investments In Affiliates Subsidiaries Associates … | - | - | - | - | - | 0 | |||||
Liabilities And Stockhold… | |||||||||||
Liabilities Current | |||||||||||
Accrued Liabilities Current | 2 | 3 | 4 | 4 | 5 | 7 | |||||
Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Convertible Notes Payable Current | 4 | 4 | 4 | 3 | 5 | 4 | |||||
Liabilities Current | 12 | 11 | 15 | 14 | 15 | 16 | |||||
Deferred Revenue Current | - | - | - | - | - | 0 | |||||
Convertible Long Term Notes Payable | 4 | 4 | 5 | 5 | 6 | 7 | |||||
Operating Lease Liability Noncurrent | - | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities | 16 | 16 | 20 | 19 | 21 | 24 | |||||
Stockholders Equity | |||||||||||
Common Stock Value | 1 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital Common Stock | 207 | 205 | 195 | 190 | 188 | 186 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -2 | -1 | -2 | -2 | -1 | -1 | |||||
Retained Earnings Accumulated Deficit | -217 | -212 | -205 | -197 | -188 | -178 | |||||
Stockholders Equity | -11 | -8 | -11 | -8 | -1 | 7 | |||||
Liabilities And Stockholders Equity | 5 | 8 | 9 | 11 | 20 | 31 | |||||
Common Stock Par Or Stated Value Per Share | 0.003 | 0 | 0.003 | 0.003 | 0.003 | 0 | |||||
Common Stock Shares Authorized | 3 | 3 | 3 | 2 | 2 | 3 | |||||
Common Stock Shares Issued | 3 | 3 | 2 | 2 | 2 | 2 | |||||
Shares Outstanding | 3 | 3 | 2 | 2 | 2 | 2 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 25.33% | 63.33% | 62.67% | - | - | - | - | - | - | - | - | - |
| 2024 | -16.98% | -16.98% | -41.13% | -9.92% | -33.88% | -42.15% | -20.46% | -54.67% | -32.10% | -28.23% | -22.97% | -11.96% |
| 2023 | - | - | - | - | - | - | - | - | - | -19.87% | -62.91% | -75.83% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Renalytix plc (RNLXY) — SEC Financial Statements & Analysis
Renalytix plc (RNLXY) is a services-medical laboratories company, incorporated in X0. Renalytix plc trades on OTC as: RNLXY, RENXF, RNLXD. Based on its latest SEC filing (Form 10-Q, period ending 2024-09-30), Renalytix plc reported a Gross Profit Margin of 12.71% (TTM), a Debt-to-Equity ratio of -1.42x, a Price-to-Sales (P/S) ratio of 117.40x (TTM), a Price-to-Book (P/B) ratio of -24.40x (TTM), at a market cap of $276.13M. Figures below are sourced from SEC EDGAR, as-filed.
- Gross Profit Margin TTM
- 12.71%
- Debt To Equity
- -1.42x
- P/S TTM
- 117.40x
- P/B TTM
- -24.40x
- Market Cap
- $276.13M
Data as of 2024-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Renalytix plc in?
Renalytix plc (RNLXY) operates in the Services-Medical Laboratories industry.
What is RNLXY's market cap?
Renalytix plc (RNLXY) has a market capitalization of $276.13M as of 2024-09-30.
What exchange does RNLXY trade on?
Renalytix plc (RNLXY) trades on the OTC.
Where is Renalytix plc incorporated?
Renalytix plc is incorporated in United Kingdom.